Related Experiment Video
Updated: Oct 19, 2026

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
Published on: December 27, 2016
[In vitro bactericidal activities of new oral penem, faropenem against the various clinical isolates]
K Matsuzaki1, T Nishiyama, M Hasegawa
1Chemotherapy Division, Mitsubishi-Kagaku Bio-Clinical Laboratories, Tokyo, Japan.
Abstract:
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of faropenem (FRPM) more compared with those of various oral beta-lactams against 15 isolates each of 6 species of microorganism. FRPM possessed potent in vitro antibacterial activity against both aerobic and anaerobic Gram-positive bacteria tested. FRPM showed the same activity as new oral cephems such as cefdinir, cefditoren and cefcapene against all Gram-negative bacteria, but K. pneumoniae strains were less susceptible. The MBC of FRPM against S. pneumoniae and the other strains tested equal and were within 1 dilution the MIC of that, respectively. These results suggest that FRPM has excellent in vitro bactericidal activity against clinical isolates and is a clinically useful for the chemotherapy of bacterial infections.
Insights
Faropenem (FRPM) demonstrates potent in vitro antibacterial activity against Gram-positive bacteria and comparable efficacy to new oral cephems against Gram-negative bacteria, suggesting its clinical utility for bacterial infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Oral beta-lactams are commonly used for bacterial infections.
- Evaluating new antibiotics like faropenem (FRPM) is crucial for expanding treatment options.
- Understanding the in vitro activity spectrum of FRPM is essential for its clinical application.
Purpose of the Study:
- To compare the in vitro antibacterial activity of faropenem (FRPM) with various oral beta-lactams.
- To determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of FRPM.
- To assess the bactericidal activity of FRPM against clinical isolates.
Main Methods:
- Testing FRPM and oral beta-lactams against 15 isolates each of 6 bacterial species.
- Determining MIC and MBC values for each antibiotic and isolate.
- Comparing the activity profiles of FRPM and reference antibiotics.
Main Results:
- FRPM exhibited potent in vitro activity against aerobic and anaerobic Gram-positive bacteria.
- FRPM showed comparable activity to new oral cephems against Gram-negative bacteria, with lower susceptibility in K. pneumoniae strains.
- The MBC of FRPM was equal to or within one dilution of the MIC for tested strains, indicating bactericidal activity.
Conclusions:
- Faropenem (FRPM) possesses excellent in vitro antibacterial and bactericidal activity against clinical isolates.
- FRPM demonstrates promising efficacy comparable to existing oral beta-lactams.
- FRPM is suggested to be a clinically useful agent for the chemotherapy of bacterial infections.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Effectiveness
Production of Antibiotics
Clinical Significance of Antibiotic Resistance
